Krystal Biotech Operating Income 2017-2024 | KRYS

Krystal Biotech operating income from 2017 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

Krystal Biotech Operating Income 2017-2024 | KRYS

Krystal Biotech operating income from 2017 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$146.3B
Gilead Sciences (GILD)$114.5B
Bristol Myers Squibb (BMY)$114.2B
Vertex Pharmaceuticals (VRTX)$108.7B
CSL (CSLLY)$83.4B
Regeneron Pharmaceuticals (REGN)$74.9B
GSK (GSK)$69.3B
Argenex SE (ARGX)$38.7B
Alnylam Pharmaceuticals (ALNY)$31.8B
BioNTech SE (BNTX)$26.8B
Illumina (ILMN)$21.7B
BeiGene (ONC)$20.5B
Biogen (BIIB)$20.5B
Incyte (INCY)$13.9B
Genmab (GMAB)$13.8B
Genmab (GNMSF)$13.7B
Intra-Cellular Therapies (ITCI)$13.4B
Moderna (MRNA)$13.1B
Insmed (INSM)$13B
Bio-Techne Corp (TECH)$12B
BioMarin Pharmaceutical (BMRN)$11.7B
Sarepta Therapeutics (SRPT)$11.3B
Vaxcyte (PCVX)$10.6B
QIAGEN (QGEN)$10.5B
Exelixis (EXEL)$10.3B
Swedish Orphan Biovitrum (BIOVF)$10.1B
Exact Sciences (EXAS)$9.6B
Bio-Rad Laboratories (BIO.B)$9.5B
Repligen (RGEN)$9B
Roivant Sciences (ROIV)$8.1B